BioMed Research International

BioMed Research International / 2013 / Article
Special Issue

Novel Drugs Development for Cardio-/ Cerebrovascular Diseases

View this Special Issue

Research Article | Open Access

Volume 2013 |Article ID 790263 |

Najah R. Hadi, Bassim I. Mohammad, Ihsan M. Ajeena, Hussam H. Sahib, "Antiatherosclerotic Potential of Clopidogrel: Antioxidant and Anti-Inflammatory Approaches", BioMed Research International, vol. 2013, Article ID 790263, 10 pages, 2013.

Antiatherosclerotic Potential of Clopidogrel: Antioxidant and Anti-Inflammatory Approaches

Academic Editor: Joen-Rong Sheu
Received17 Sep 2013
Revised07 Dec 2013
Accepted07 Dec 2013
Published26 Dec 2013


Background. Atherosclerosis is characterized by endothelial dysfunction, vascular inflammation, and the buildup of lipids, cholesterol, calcium, and cellular debris within the intima of the walls of large and medium size arteries. Objective. To evaluate the effect of clopidogrel on atherosclerosis progression. Materials and Methods. A total of 28 local domestic rabbits were assigned to four groups: normal control, atherogenic control, vehicle control, and clopidogrel treated. Serum triglycerides, total cholesterol, HDL-C, plasma high sensitive C-reactive protein (hsCRP), plasma malondialdehyde (MDA), and plasma reduced glutathione (GSH) were measured at the end of the experiment. Immunohistochemical of aortic atherosclerotic changes were also performed. Results. There was no statistically significant difference between atherogenic control group and vehicle group. Levels of lipid profile, atherogenic index, hsCRP, and MDA are increased while GSH levels were decreased in animals on atherogenic diet. Immunohistochemical analysis showed that aortic expressions of VCAM-1, MCP-1, TNF-α, and IL-17A were significantly increased in atherogenic control group. Histopathologic finding showed that animals on atherogenic diet have significant atherosclerotic lesion. Compared to atherogenic control group clopidogrel do not have significant effect on lipid profile. Clopidogrel significantly reduces hsCRP and MDA levels and increases GSH level. Furthermore, clopidogrel treatment significantly reduced aortic expressions parameters and the histopathologic examination of the aortic arch showed a significant reduction of atherosclerotic lesion. Conclusions. This study outlines how clopidogrel reduces lipid peroxidation, systemic inflammation, and aortic expression of inflammatory markers and hence reduces the progression of atherosclerosis.

1. Introduction

Atherosclerosis is a disease of large- and medium-sized arteries and is characterized by endothelial dysfunction, vascular inflammation, and the buildup of lipids, cholesterol, calcium, and cellular debris within the intima of the vessel wall. This buildup results in plaque formation, vascular remodelling, acute and chronic luminal obstruction, abnormalities of blood flow, and diminished oxygen supply to target organs [1]. The proposed initial step in atherogenesis is endothelial dysfunction leading to a number of compensatory responses that alter the normal vascular homeostatic properties [2]. Proinflammatory stimuli, including a diet high in saturated fat, hypercholesterolemia, obesity, hyperglycemia, insulin resistance, hypertension, and smoking, trigger the endothelial expression of adhesion molecules such as P-selectin, E-selectin, ICAM-1, and VCAM-1 which mediate the attachment of circulating monocytes and lymphocyte [3, 4]. Atherosclerotic lesions develop as a result of inflammatory stimuli, subsequent release of various cytokines, proliferation of smooth muscle cells, synthesis of connective tissue matrix, and accumulation of macrophage and lipid. Atherosclerosis is likely initiated when endothelial cells overexpress adhesion molecules in response to turbulent flow in the setting of an unfavorable serum lipid profile. Clopidogrel inhibits ADP receptors on platelets, blocking GP11b/111a complex and as a result, inhibiting platelet aggregation. Animals that were fed a pro-atherogenic diet rapidly overexpress vascular cell adhesion molecule-1 (VCAM-1) [5]. VCAM-1 expression increases recruitment of monocytes and T cells to sites of endothelial injury; subsequent release of monocyte chemoattractant protein-1 (MCP-1) by leukocytes magnifies the inflammatory cascade by recruiting additional leukocytes, activating leukocytes in the media, and causing recruitment and proliferation of smooth muscle cells [6]. However, in response to signals generated within the early plaque, monocytes adhere to the endothelium and then migrate through the endothelium and basement membrane by elaborating enzymes, including locally activated matrix metalloproteinase (MMP) that degrade the connective tissue matrix. Recruited macrophages both release additional cytokines and begin to migrate through the endothelial surface into media of the vessel. This process is further enhanced by the local release of monocytes-colony stimulating factor (M-CSF), which causes monocytic proliferation; local activation of monocytes leads to both cytokine-mediated progression of atherosclerosis and oxidation of low-density lipoprotein (LDL) [7].

Platelets serve major functions in three key aspects of atherosclerosis: atherogenesis, inflammation, and atherothrombosis [8]. Therefore, the present study was undertaken to evaluate the effect of clopidogrel on the progression of atherosclerosis.

2. Materials and Methods

2.1. Animals

A total of 28 local domestic rabbits, weighing (1.1–1.5) kg, were used in this study. All experiments were conducted in the Department of Pharmacology, College of Medicine, Qadaysia University, according to the guidelines for the Care and Use of Laboratory Animals in scientific research. The animals were placed in an animal house, in a group caging system, at controlled temperature ( °C) and ambient humidity. Lights were maintained on a 12-h light/dark cycle. The animals had free access to water ad libitum.

2.2. Drugs

Clopidogrel (plavix, sanofi aventis, BN.F-33565, France) was dissolved in ethanol (10%) [9] and used in a dose of 20 mg/kg/day [10]. A solution of drug was freshly prepared and administered once daily orally according to body weight through stomach tube.

2.3. Animal Model of Atherosclerosis

Induction of atherosclerosis was carried out by feeding the rabbit an atherogenic diet (2% cholesterol (BDH Chemicals Ltd Poole England, prod 43011) enriched rabbit chow) made by addition of cholesterol powder to chow pellets for 8 weeks [11, 12].

2.4. Experimental Protocol

After 2 weeks of acclimatization period, the animals were randomized into 4 groups (of 7 rabbits each): normal diet control group (NC, Group I), high-cholesterol diet group which served as atherogenic control (AC, Group II), high-cholesterol diet with ethanol group (vehicle, Group III), and high-cholesterol diet with clopidogrel group (Group IV). The NC group was fed normal rabbit chow, whereas the high-cholesterol diet groups were fed a 2% high-cholesterol (atherogenic) diet. The duration of treatment was 8 weeks. At the end of the experiment, food was withheld for 16–18 hours and animals were anesthetized by ketamine (HIKMA pharmaceuticals B.N 3310) at 66 mg/kg and xylazine (alfasan B.N 1004111-07) at 6 mg/kg intramuscular [13]. The chest was opened by thoracotomy, blood sample was collected directly from the heart, and aorta was separated.

After that, the following investigations were performed:(i)lipid profile including total serum cholesterol (TC), low density lipoprotein (LDL), and high density lipoprotein (HDL),(ii)immunohistochemistray for assessment of VCAM, TNFα, MCP1 and IL-17A,(iii)oxidation parameter including MDA and GSH,(iv)systemic inflammatory marker hsCRP,(v)histopathological examination of the aorta for assessment of atherosclerosis.

All specimens were immediately fixed in 10% formaldehyde solution for subsequent processing.

2.5. Biochemical Procedures

Serum lipid profile, including total cholesterol and TG, was determined by enzymatic methods using an automatic analyzer (Abbott, Alcyon 300, USA). Plasma GSH levels was determined using methods of Beutler [14]. Plasma MDA level were determined by using competitive inhibition enzyme immunoassay technique (cusabio; Catalog no. CSB-E13712Rb). The determination of hsCRP was done by using rabbit high-sensitive CRP ELISA kit supplied by (Kamiya Biomedical Company; Cat. no. KT-097). The measurement was carried out according to the manufacturer’s instructions.

2.6. Histological Examination of the Aorta

For histological evaluation of atherosclerosis, the specimens were processed in usual manner and embedded in paraffin and cut into 5 μm thick sections. The tissue sections were stained with hematoxylin and eosin. The assessment of atherosclerotic changes was performed according to the American Heart Association classification of atherosclerosis: Type I and Type II lesions (early lesions), Type III lesions (intermediate lesions or preatheroma), Type IV lesions (atheroma), Type V lesions (fibroatheroma or advance lesion), and Type VI lesions (complicated lesions) [15] (Figure 1).

2.7. Immunohistochemistry

It was performed with polyclonal goat antibodies and raised against rabbit VCAM-1, TNFα, MCP-1, and IL-17A. Staining procedure was carried out according to the manufacturer’s instructions (Santa Cruz Biotechnology, Inc). The stain intensity was scored to 0: indicated no staining, 1: weak, 2: moderate, 3: strong, and 4: very strong stain intensity [16] (Figures 2, 3, 4, and 5).

2.8. Statistical Analysis

Statistical analyses were performed using SPSS 12.0 version. Data were expressed as mean ± SEM. Paired -test was used to compare the mean values within each group at different time. Analysis of Variance (ANOVA) was used for the multiple comparison among all groups. The histopathological grading was assessed by Mann-Whitney test. In all tests, was considered to be statistically significant.

3. Results

3.1. Effect of High-Cholesterol Diet

There was no statistically significant difference between AC group and vehicle group. Compared to NC group, the AC showed significant changes in serum lipid profile, oxidation, and inflammatory markers. Serum levels of TC, TG and LDL-C as well as plasma levels of MDA and hs-CRP were significantly ( ) increased. In addition plasma levels of GSH were significantly ( ) lower in rabbits that fed on cholesterol-enriched diet in comparison to animals on normal diet (Tables 1, 2, and 3).

Clopidogrel treatedACNCVC

TC (mg/dL)
TG (mg/dL)
HDL (mg/dL)
LDL (mg/dL)
VLDL (mg/dL)

Results are expressed as mean ± SEM.
, as compared to NC group.
NNot significant as compared to AC group.

Clopidogrel treatedACNCVC

Plasma GSH (mmol/L)
Plasma MDA ( mol/L)
Plasma hsCRP ( g/L)

Results are expressed as mean ± SEM.
, as compared to NC group; , as compared to AC group.
NNot significant as compared to AC group.

Clopidogrel treatedACNCVC

VCAM-1Moderate**Very strong*Negative Very strong*
MCP-1Moderate**Very strong*NegativeVery strong*
TNF Moderate**Very strong*NegativeVery strong*
IL-17 AModerate**Very strong*NegativeVery strong*

, as compared to NC group.
, as compared to AC group.
3.2. Effects of Clopidogrel Treatment

Compared to atherogenic control, treating hyperlipidemic rabbits with clopidogrel resulted in significantly ( ) lower levels of plasma hs-CRP and MDA. However, clopidogrel treatment caused no significant alteration ( ) in the levels of serum lipids and GSH (Tables 2 and 3).

3.3. Immunohistochemistry

The results of immunohistochemical analysis for rabbit’s aortic arch of VCAM-1, MCP-1, TNF-alpha, and IL-17A were significantly different between the 4 study groups. The median intensity of these markers was the highest in AC group (very strong for all markers) and the lowest in NC group (normal for all markers). Clopidogrel treated group was associated with a median stain intensity of moderate for VCAM-1, MCP-1, TNF-alpha, and IL-17A that is significantly lower than the atherogenic control (Figure 6).

3.4. Histopathological Findings

The atherosclerotic lesions of aortic arch were graded as normal, initial, intermediated, advance, and complicated lesions (Figure 1). The median histopathological grade of atherosclerotic changes was significantly different between the 4 study groups. The median was the highest in atherogenic control (advance) and the lowest in the normal diet control (no abnormality). Clopidogrel treated group was associated with a median aortic change (initial) that is significantly lower than the atherogenic control (Figure 7).

4. Discussion

4.1. Effect of Clopidogrel on Lipid Profile

In this study clopidogrel had small nonsignificant effect on lipid profile in comparison with induced untreated study group. Such findings are consistent with that of Gu and his followers [17].

4.2. Effect of Clopidogrel on Oxidation Stress and Inflammatory Parameters

Like what Srinivas and his followers concluded in 2008 [18], the results showed that clopidogrel had significant effect on plasma MDA and GSH levels. Clopidogrel inhibited the increased plasma MDA level in AC group and it increased the plasma GSH level that was lowered in AC group. Furthermore, the results demonstrated a significant effect of clopidogrel on inflammatory acute phase protein by reducing the elevated hsCRP in rabbits on high fat diet. This finding suggests that the anti-inflammatory activity of clopidogrel on the vascular inflammatory responses is induced by high fat diet. This hypothesis is supported by similar findings and conclusions of other researchers [19, 20].

4.3. Effect of Clopidogrel on Aortic Expression of Immunohistochemistry Parameters (VCAM-1, MCP-1, TNF-α, and IL-17)

The significant reduction of elevated VCAM-1, MCP-1, TNF-α, IL-17 in atherosclerosis model of hypercholesterolemia rabbit shows the effect of clopidogrel on such inflammatory markers. This finding was also reported by Li and his followers [21]. So, clopidogrel can reduce inflammation that underlies the chronic process of atherosclerosis by reducing platelet-dependent upregulation of inflammatory and proatherothrombotic functions in leukocytes [22]. The present study is one of the very few studies that demonstrated that clopidogrel treatment significantly suppress atherosclerotic lesion induced by atherogenic diet in rabbits as compared with induced untreated group [21]. Clopidogrel will reduce expression of hsCRP and platelet-derived growth factor and also reduce intimal thickness. These results suggest that clopidogrel can retard the progression of established lesions related to inhibiting inflammation, cell proliferation, and promotion of cell apoptosis [23].

The role of IL-17A in atherosclerosis remains controversial, with different studies suggesting either a proatherogenic or an atheroprotective role. Taleb and his followers revealed that the loss of suppressor of cytokine signalling (SOCS) 3 in T cells increased both IL-17 and IL-10 production which induced an anti-inflammatory macrophage phenotype and subsequently led to unexpected IL-17-dependent reduction in lesion development and vascular inflammation [24]. On the other hand, Smith and his followers demonstrated that IL-17A plays a proatherogenic inflammatory role during atherogenesis by promoting monocyte/macrophage recruitment into the aortic wall [25]. Furthermore, Pietrowski and his followers reported that IL-17A induced an increased level of reactive oxygen species (ROS) in vascular smooth muscle cells (VSMC) [26].

We recommend further studies to use the Watanabe hereditary hyperlipidemic (WHHL) rabbit model where atherosclerosis already happened and no time is needed for induction of atherosclerosis as compared with cholesterol fed model of atherosclerosis. Furthermore, lipoprotein metabolism, atherosclerotic plaques, and coronary artery disease in WHHL rabbit model resemble those that happened in human [27]. Additionally, noninvasive imaging studies like IRON-MRI contrast imaging may be used which precisely highlight macrophage-rich plaques [28] to further clarify the effect of clopidogrel on atherosclerosis.

In conclusion, this study outlines how clopidogrel reduces lipid peroxidation, systemic inflammation, and aortic expression of inflammatory markers and hence reduces the progression of atherosclerosis.

Conflict of Interests

The authors declare that there is no conflict of interests regarding this paper.


  1. T. J. Anderson, “Assessment and treatment of endothelial dysfunction in humans,” Journal of the American College of Cardiology, vol. 34, no. 3, pp. 631–638, 1999. View at: Google Scholar
  2. K. Pyorala, M. Laakso, and M. Uusitupa, “Diabetes and atherosclerosis: an epidemiologic view,” Diabetes/Metabolism Reviews, vol. 3, no. 2, pp. 463–524, 1987. View at: Google Scholar
  3. J. Fan and T. Watanabe, “Inflammatory reactions in the pathogenesis of atherosclerosis,” Journal of Atherosclerosis and Thrombosis, vol. 10, no. 2, pp. 63–71, 2003. View at: Google Scholar
  4. R. R. S. Packard and P. Libby, “Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction,” Clinical Chemistry, vol. 54, no. 1, pp. 24–38, 2008. View at: Publisher Site | Google Scholar
  5. H. Li, M. I. Cybulsky, M. A. Gimbrone Jr., and P. Libby, “An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium,” Arteriosclerosis and Thrombosis, vol. 13, no. 2, pp. 197–204, 1993. View at: Google Scholar
  6. P. Libby, “Inflammation in atherosclerosis,” Nature, vol. 420, no. 6917, pp. 868–874, 2002. View at: Publisher Site | Google Scholar
  7. S. K. Clinton, R. Underwood, L. Hayes, M. L. Sherman, D. W. Kufe, and P. Libby, “Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis,” The American Journal of Pathology, vol. 140, no. 2, pp. 301–316, 1992. View at: Google Scholar
  8. G. Davì and C. Patrono, “Platelet activation and atherothrombosis,” The New England Journal of Medicine, vol. 357, pp. 2482–2494, 2007. View at: Google Scholar
  9. C. Cayman, “Product information, clopidogrel,” View at: Google Scholar
  10. J.-M. Herbert, F. Dol, A. Bernat, R. Falotico, A. Lalé, and P. Savi, “The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit,” Thrombosis and Haemostasis, vol. 80, no. 3, pp. 512–518, 1998. View at: Google Scholar
  11. M. Sasani, B. Yazgan, I. Celebi et al., “Hypercholesterolemia increases vasospasm resulting from basilar artery subarachnoid hemorrhage in rabbits which is attenuated by Vitamin,” Surgical Neurology International, vol. 14, no. 2, p. 29, 2011. View at: Google Scholar
  12. A. Daugherty, B. S. Zweifel, and G. Schonfeld, “Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits,” British Journal of Pharmacology, vol. 98, no. 2, pp. 612–618, 1989. View at: Google Scholar
  13. T. Hayashi, J. M. Fukuto, L. J. Ignarro, and G. Chaudhuri, “Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 23, pp. 11259–11263, 1992. View at: Publisher Site | Google Scholar
  14. E. Beutler, O. Duron, and B. M. Kelly, “Improved method for the determination of blood glutathione,” The Journal of Laboratory and Clinical Medicine, vol. 61, pp. 882–888, 1963. View at: Google Scholar
  15. S. L. Mumford, Labrotory Procedure Manual, USFWS, Olympia Fish Health Center, Washington, DC, USA, 2nd edition, 2004.
  16. Y.-H. Chen, S.-J. Lin, J.-W. Chen, H.-H. Ku, and Y.-L. Chen, “Magnolol attenuates VCAM-1 expression in vitro in TNF-α-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits,” British Journal of Pharmacology, vol. 135, no. 1, pp. 37–47, 2002. View at: Google Scholar
  17. Q. Gu, J.-L. Chen, and Y.-M. Ruan, “Inhibitory effects of aspirin, clopidogrel, and their combination on the progression of atherosclerosis in rabbits,” Chinese Medical Journal, vol. 27, no. 1, pp. 87–91, 2005. View at: Google Scholar
  18. M. Srinivas, A. Annapurna, and Y. N. Reddy, “Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats,” Indian Journal of Experimental Biology, vol. 46, no. 10, pp. 698–703, 2008. View at: Google Scholar
  19. T. Heitzer, V. Rudolph, E. Schwedhelm et al., “Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1648–1652, 2006. View at: Publisher Site | Google Scholar
  20. S. R. Steinhubl, J. J. Badimon, D. L. Bhatt, J.-M. Herbert, and T. Lüscher, “Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease,” Vascular Medicine, vol. 12, no. 2, pp. 113–122, 2007. View at: Publisher Site | Google Scholar
  21. M. Li, Y. Zhang, H. Ren, Y. Zhang, and X. Zhu, “Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model,” Atherosclerosis, vol. 194, no. 2, pp. 348–356, 2007. View at: Publisher Site | Google Scholar
  22. V. Evangelista, S. Manarini, G. Dell'Elba et al., “Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation,” Thrombosis and Haemostasis, vol. 94, no. 3, pp. 568–577, 2005. View at: Publisher Site | Google Scholar
  23. H. Ren, M. Li, L. Feng et al., “Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model,” Journal of Cardiovascular Pharmacology, vol. 55, no. 6, pp. 617–624, 2010. View at: Publisher Site | Google Scholar
  24. S. Taleb, M. Romain, B. Ramkhelawon et al., “Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis,” Journal of Experimental Medicine, vol. 206, no. 10, pp. 2067–2077, 2009. View at: Publisher Site | Google Scholar
  25. E. Smith, K.-M. R. Prasad, M. Butcher et al., “Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 121, no. 15, pp. 1746–1755, 2010. View at: Publisher Site | Google Scholar
  26. E. Pietrowski, B. Bender, J. Huppert, R. White, H. J. Luhmann, and C. R. W. Kuhlmann, “Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)H-oxidase derived reactive oxygen species,” Journal of Vascular Research, vol. 48, no. 1, pp. 52–58, 2011. View at: Publisher Site | Google Scholar
  27. M. Shiomi and T. Ito, “The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe,” Atherosclerosis, vol. 207, no. 1, pp. 1–7, 2009. View at: Publisher Site | Google Scholar
  28. G. Korosoglou, R. G. Weiss, D. A. Kedziorek et al., “Noninvasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using “positive contrast” magnetic resonance imaging,” Journal of the American College of Cardiology, vol. 52, no. 6, pp. 483–491, 2008. View at: Publisher Site | Google Scholar

Copyright © 2013 Najah R. Hadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.